Skip to main content

Johnson & Johnson execs offer upbeat view of second-half recovery from COVID-19 pandemic

Johnson & Johnson executives had a surprisingly rosy take about an economic recovery in the second half of the year even as the COVID-19 pandemic cratered the company’s $25 billion medical device business in the first quarter of 2020.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.